{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:53:17Z","timestamp":1777866797835,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"BC Mental Health and Addictions Services"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.neuropharm.2011.02.019","type":"journal-article","created":{"date-parts":[[2011,3,7]],"date-time":"2011-03-07T15:37:16Z","timestamp":1299512236000},"page":"1391-1400","source":"Crossref","is-referenced-by-count":42,"title":["Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats"],"prefix":"10.1016","volume":"62","author":[{"given":"H.N.","family":"Boyda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.C.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2011.02.019_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.amepre.2008.11.020","article-title":"Obesity among those with mental disorders: a National Institute of Mental Health meeting report","volume":"36","author":"Allison","year":"2009","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib3","first-page":"121","article-title":"An animal model of antipsychotic-induced weight gain","volume":"152","author":"Arjona","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2008.06.105","article-title":"The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063","volume":"592","author":"Assie","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"Baptista","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib6","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/j.1460-9568.2008.06233.x","article-title":"Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins","volume":"27","author":"Barr","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.0953-816X.2004.03457.x","article-title":"Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia","volume":"20","author":"Barr","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A\u00a0parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2008.06.006","article-title":"Insulin resistance following continuous, chronic olanzapine treatment: an animal model","volume":"104","author":"Chintoh","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.pnpbp.2010.04.003","article-title":"The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine","volume":"34","author":"Chiu","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib14","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.lfs.2007.08.009","article-title":"Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats","volume":"81","author":"Choi","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A\u00a0parametric analysis of olanzapine-induced weight gain in female rats","volume":"181","author":"Cooper","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0269881106069637","article-title":"Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities","volume":"21","author":"Cooper","year":"2007","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pbb.2010.05.029","article-title":"Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats","volume":"97","author":"Evers","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-007-0833-9","article-title":"The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats","volume":"194","author":"Fell","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/0269881107082287","article-title":"Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats","volume":"22","author":"Fell","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.euroneuro.2003.12.001","article-title":"Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats","volume":"14","author":"Fell","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00213-005-0131-3","article-title":"Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats","volume":"182","author":"Fell","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/070674371005500302","article-title":"Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making","volume":"55","author":"Foussias","year":"2010","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11892-010-0112-8","article-title":"Metabolic syndrome associated with schizophrenia and atypical antipsychotics","volume":"10","author":"Hasnain","year":"2010","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1176\/appi.ajp.2008.08030383","article-title":"Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents","volume":"166","author":"Haupt","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1258\/002367798780599866","article-title":"Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink","volume":"32","author":"Hem","year":"1998","journal-title":"Lab. Anim."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib29","article-title":"A\u00a0translational research approach to poor treatment response in patients with schizophrenia: clozapine\u2013antipsychotic polypharmacy","volume":"34","author":"Honer","year":"2009","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/00023210-200721090-00001","article-title":"Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia","volume":"21","author":"Honer","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00213-005-0081-9","article-title":"Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats","volume":"182","author":"Kalinichev","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00008877-200605000-00009","article-title":"Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine","volume":"17","author":"Kalinichev","year":"2006","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A\u00a028-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","article-title":"Treatment with antipsychotics and the risk of diabetes in clinical practice","volume":"197","author":"Kessing","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib37","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1301\/nr.2003.dec.397-412","article-title":"Evaluation of insulin sensitivity in clinical practice and in research settings","volume":"61","author":"Monzillo","year":"2003","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib41","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1152\/ajpendo.00645.2007","article-title":"Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage","volume":"294","author":"Muniyappa","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"Suppl. 4","key":"10.1016\/j.neuropharm.2011.02.019_bib42","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib43","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.lfs.2007.04.001","article-title":"Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects","volume":"80","author":"Park","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2006.09.009","article-title":"Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain","volume":"551","author":"Patil","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0091-3057(03)00042-X","article-title":"Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human","volume":"75","author":"Pouzet","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/11533710-000000000-00000","article-title":"Medication errors in psychiatry: a comprehensive review","volume":"24","author":"Procyshyn","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"Procyshyn","year":"2010","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib48","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib49","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/schbul\/sbq083","article-title":"Antipsychotic dosing: how much but also how often?","volume":"36","author":"Remington","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib50","article-title":"\u201cExtended\u201d antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial","author":"Remington","year":"2010","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Bull"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib53","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"\u201cBreakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib54","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2011.02.019_bib55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1\u00a0p.oduction and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib56","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug\u2013drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2010.05.009","article-title":"Olanzapine affects locomotor activity and meal size in male rats","volume":"97","author":"van der Zwaal","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2011.02.019_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0028-1103293","article-title":"Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund","volume":"42","author":"Weinbrenner","year":"2009","journal-title":"Pharmacopsychiatry"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081100089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081100089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T23:50:24Z","timestamp":1560037824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081100089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S002839081100089X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2011.02.019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9520956.10172054","asserted-by":"object"}]},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}